A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

PHASE3CompletedINTERVENTIONAL
Enrollment

954

Participants

Timeline

Start Date

March 1, 2013

Primary Completion Date

November 13, 2016

Study Completion Date

March 10, 2021

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing.

DRUG

Sorafenib

400 mg twice daily (BID) oral dosing.

Trial Locations (186)

59037

Facility # 1, Nord

75013

Facility # 1, Paris

75020

Facility # 1, Paris

Unknown

Facility # 1, Los Angeles

Facility # 1, Sacramento

Facility # 1, San Francisco

Facility # 1, Washington D.C.

Facility # 1, Tampa

Facility # 1, Duluth

Facility # 1, Lawrenceville

Facility # 1, Baltimore

Facility # 1, Detroit

Facility # 1, Kansas City

Facility # 1, St Louis

Facility # 1, East Orange

Facility # 1, Brooklyn

Facility # 1, Lake Success

Facility # 1, New York

Facility # 1, Charlotte

Facility # 1, Durham

Facility # 1, Portland

Facility # 1, Austin

Facility # 1, Lubbock

Facility # 1, Seattle

Facility # 1, Camperdown

Facility # 1, Wentworthville

Facility # 1, Woolloongabba

Facility # 1, Fitzroy

Facility # 1, Melbourne

Facility # 2, Melbourne

Facility # 1, Nedlands

Facility # 1, Brussels

Facility # 1, Edegem

Facility # 1, Liège

Facility # 1, Ottawa

Facility # 1, Hefei

Facility # 1, Beijing

Facility # 2, Beijing

Facility # 3, Beijing

Facility # 1, Chongqing

Facility # 1, Fuzhou

Facility # 2, Fuzhou

Facility # 1, Guangzhou

Facility # 1, Harbin

Facility # 1, Changsha

Facility # 1, Nanjing

Facility # 1, Suzhou

Facility # 1, Changchun

Facility # 1, Dalian

Facility # 1, Jinan

Facility # 1, Shanghai

Facility # 3, Shanghai

Facility # 1, Xi’an

Facility # 2, Xi’an

Facility # 1, Hangzhou

Facility # 1, Tianjin

Facility # 1, Nice

Facility # 1, Pessac

Facility # 1, Toulouse

Facility # 1, Montpellier

Facility # 1, Rennes

Facility # 1, Vandœuvre-lès-Nancy

Facility # 1, Amiens

Facility # 1, Créteil

Facility # 1, Bordeaux

Facility # 1, Lille

Facility # 1, Lyon

Facility # 1, Rhone

Facility # 1, Heidelberg

Facility # 1, Tübingen

Facility # 1, Marburg

Facility # 1, Hanover

Facility # 1, Cologne

Facility # 1, Essen

Facility # 1, Mainz

Facility # 1, Hong Kong

Facility # 2, Hong Kong

Facility # 3, Hong Kong

Facility # 1, Kowloon

Facility # 1, Petah Tikva

Facility # 1, Torrette

Facility # 1, Bari

Facility # 1, Benevento

Facility # 1, Bologna

Facility # 1, Napoli

Facility # 2, Napoli

Facility # 1, Palermo

Facility # 1, Roma

Facility # 1, Nagoya

Facility # 1, Kashiwa

Facility # 1, Matsuyama

Facility # 1, Kurume

Facility # 1, Sapporo

Facility # 2, Sapporo

Facility # 1, Nishinomiya

Facility # 1, Kanazawa

Facility # 1, Kawasaki

Facility # 1, Yokohama

Facility # 1, Tsu

Facility # 1, Ōmura

Facility # 1, Ōsaka-sayama

Facility # 1, Bunkyo-Ku

Facility # 1, Chuo-ku

Facility # 1, Koto-ku

Facility # 1, Minato-ku

Facility # 1, Musashino

Facility # 1, Shimonoseki

Facility # 1, Fukuoka

Facility # 1, Hiroshima

Facility # 1, Okayama

Facility # 2, Osaka

Facility # 1, Saga

Facility # 2, Saga

Facility # 1, Kuantan

Facility # 1, George Town

Facility # 1, Miri

Facility # 1, Batu Caves

Facility # 1, Kuala Lumpur

Facility # 1, Cebu City

Facility # 2, Cebu City

Facility # 1, Davao City

Facility # 1, Quezon City

Facility # 2, Quezon City

Facility # 1, Gdansk

Facility # 1, Warsaw

Facility # 1, Wroclaw

Facility # 1, Arkhangelsk

Facility # 1, Moscow

Facility # 2, Moscow

Facility # 3, Saint Petersburg

Facility # 4, Saint Petersburg

Facility # 1, Ufa

Facility # 1, Singapore

Facility # 2, Singapore

Facility # 3, Singapore

Facility # 4, Singapore

Facility # 1, Goyang-si

Facility # 1, Seongnam-si

Facility # 2, Seongnam-si

Facility # 1, Suwon

Facility # 1, Daegu

Facility # 1, Hwasun

Facility # 1, Busan

Facility # 2, Busan

Facility # 3, Busan

Facility # 1, Incheon

Facility # 1, Seoul

Facility # 2, Seoul

Facility # 3, Seoul

Facility # 4, Seoul

Facility # 5, Seoul

Facility # 6, Seoul

Facility # 7, Seoul

Facility # 8, Seoul

Facility # 1, L'Hospitalet de Llobregat

Facility # 1, Santander

Facility # 1, Badajoz

Facility # 1, Girona

Facility # 1, Madrid

Facility # 2, Madrid

Facility # 3, Madrid

Facility # 4, Madrid

Facility # 1, Kaohsiung City

Facility # 2, Kaohsiung City

Facility # 1, Taichung

Facility # 2, Taichung

Facility # 1, Tainan City

Facility # 2, Tainan City

Facility # 1, Taipei

Facility # 2, Taipei

Facility # 3, Taipei

Facility # 4, Taipei

Facility # 5, Taipei

Facility # 1, Taoyuan

Facility # 1, Bangkoknoi

Facility # 1, Pathum Wan

Facility # 1, Ratchathewi

Facility # 1, Muang

Facility # 1, Muang

Facility # 1, London

Facility # 3, London

Facility # 1, Manchester

Facility # 1, Liverpool

Facility # 1, Glasgow

Facility # 1, Birmingham

W12 OHS

Facility # 2, London

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Eisai Limited

INDUSTRY

NCT01761266 - A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter